Clinical Trial · NCT05672082

Contribution of [18F]DPA-714 PET for Grading and Exploration of the Inflammatory Microenvironment of Glioma.

Overview

The 18-kDa translocator protein (TSPO) is a mitochondrial protein that is weakly expressed in the healthy brain. However, there is an increase in the expression of TSPO in glial tumors. It is even associated with a higher malignancy and a shorter survival of patients. Among the different TSPO ligands, the most commonly used tracers in PET imaging are \[18F\]DPA-714 and 18F-GE180. We hypothesize that \[18F\]DPA-714 PET could improve the current performance for tumor grade definition in vivo, which is a major issue for the therapeutic management of gliomas.

Sponsor

Centre Eugène Marquis

Phase

N/A

Contacts

Xavier PALARD NOVELLO, Dr (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT05672082

Drug / Compound

DPA-714

Isotope(s):

Target(s):

TSPO

Ligand Class: Small Molecules

Eligibility

Inclusion

Suspicion of an operable diffuse glioma

Exclusion

Surgical urgency (less than 8 days between the suspected diagnosis and surgery)
Suspicion of grade I glioma